Contact SRI Biosciences
Mammalian Toxicology
SRI's Mammalian Toxicology Program is an integral part of the safety evaluation services that SRI provides to clients and partners. Our capabilities in mammalian toxicology include studies in:
- Mice
- Rats
- Hamsters
- Guinea Pigs
|
|
Clients can choose from a wide spectrum of administration routes. Working with the client, we design the required protocols and ensure that regulatory guidelines from around the world are followed.
We perform the full spectrum of toxicology studies typically required for new pharmaceuticals and biotechnology products including:
|
|
- Subchronic
- Carcinogenicity
|
- Reproductive
- Safety Pharmacology
|
In addition, we can test biomedical engineering products and medical devices in a variety of protocols. We have experience with a wide range of therapeutic agents, such as:
- Anticancer drugs
- Anti-HIV compounds
- Vaccines
- Antisense therapeutics
|
- Nucleosides
- Peptides
- Proteins
- Growth factors
|
Our experience allows us to offer more than routine testing. Specialized protocols for mechanistic investigations of target-tissue and target-cell toxicities can be developed to meet your needs. Our necropsy, histopathology and clinical pathology capabilities are first-class and are monitored by a Board-certified pathologist and our internal Quality Assurance Unit. Using the LABCAT automated data capture system, we can provide a variety of individual and summary tables as well as complete statistical evaluations. All our procedures and facilities are routinely audited and maintained under GLP regulations.
Contact Us
Last Updated Mar 19, 2009
|